SLC6A3 and Parkinson disease: Among individuals diagnosed with Parkinson disease with pathogenic variants in the LRRK2 gene, compared with those with CSF alpha-synuclein aggregates, those without evidence of aggregated alpha-synuclein have higher putamenal dopamine transporter binding and exhibit less severe motor manifestations and decline over up to 4 years.